KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBT: 2009-2024

Historic EBT for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$69.9 million.

  • Arbutus Biopharma's EBT rose 60.81% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.89%. This contributed to the annual value of -$69.9 million for FY2024, which is 4.02% up from last year.
  • Per Arbutus Biopharma's latest filing, its EBT stood at -$69.9 million for FY2024, which was up 4.02% from -$72.8 million recorded in FY2023.
  • In the past 5 years, Arbutus Biopharma's EBT registered a high of -$63.7 million during FY2020, and its lowest value of -$76.2 million during FY2021.
  • For the 3-year period, Arbutus Biopharma's EBT averaged around -$69.3 million, with its median value being -$69.9 million (2024).
  • In the last 5 years, Arbutus Biopharma's EBT skyrocketed by 61.69% in 2020 and then dropped by 19.61% in 2021.
  • Yearly analysis of 5 years shows Arbutus Biopharma's EBT stood at -$63.7 million in 2020, then decreased by 19.61% to -$76.2 million in 2021, then climbed by 14.74% to -$65.0 million in 2022, then dropped by 12.05% to -$72.8 million in 2023, then increased by 4.02% to -$69.9 million in 2024.